After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, ZNTL falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Zentalis Pharmaceuticals Inc is $96.09M. A total of 0.57 million shares were traded on the day, compared to an average of 706.72K shares.
In the most recent transaction, Matrix Capital Management Comp sold 7,500,000 shares of ZNTL for 1.33 per share on Dec 15 ’25. After the transaction, the 10% Owner now owns 6,459,973 company shares. In a previous transaction on Apr 30 ’25, Myers Scott Dunseth bought 21,000 shares at 1.40 per share. ZNTL shares that Director owns now total 281,192.
Among the insiders who bought shares, Bruns Ingmar acquired of 20,000 shares on Feb 06 ’25 at a per-share price of $2.28. This resulted in the Chief Medical Officer holding 36,629 shares of ZNTL after the transaction. In another insider transaction, Cam Gallagher bought 687 shares at $2.00 per share on Feb 11 ’25.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, ZNTL has a high of $3.33 and a low of $1.01.
As of this writing, ZNTL has an earnings estimate of -$0.4 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$0.25 per share and a lower estimate of -$0.53. The company reported an EPS of -$0.61 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. ZNTL’s latest balance sheet shows that the firm has $339.89M in Cash & Short Term Investments as of fiscal 2021. There were $44.46M in debt and $43.94M in liabilities at the time. Its Book Value Per Share was $3.50, while its Total Shareholder’s Equity was $364.48M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ZNTL is Buy with a score of 3.80.
